Thursday, June 25, 2026
🇺🇸 FDA

Clinical Tools · Cardiology · Atrial Fibrillation

CHA₂DS₂-VASc Score Calculator

Calculate the CHA₂DS₂-VASc stroke risk score for non-valvular atrial fibrillation. Built for anticoagulation decision support, ESC/AHA guideline context, and anticoagulant trial endpoint literacy.

Quick Answer

The CHA₂DS₂-VASc score estimates annual stroke risk in non-valvular atrial fibrillation from congestive heart failure, hypertension, age, diabetes, prior stroke/TIA, vascular disease, and sex category (0–9 points). Scores ≥2 generally support oral anticoagulation per ESC and AHA guidelines. Pharma teams use CHA₂DS₂-VASc for AFib trial enrichment and alongside HAS-BLED for anticoagulant development context.

CHA₂DS₂-VASc components
C (+1) · H (+1) · A2 age ≥75 (+2) · D (+1) · S2 stroke/TIA/TE (+2) · V (+1) · A age 65–74 (+1) · Sc female (+1)
Male sex = 0 points. Age categories are mutually exclusive. Maximum score = 9.

Calculate CHA₂DS₂-VASc Score

Select sex, enter age, and mark applicable risk factors for non-valvular atrial fibrillation stroke risk stratification.

Demographics

<65 = 0 · 65–74 = +1 · ≥75 = +2

Sex category
Clinical risk factors

Vascular disease: prior MI, peripheral artery disease, or aortic atherosclerotic plaque.

CHA₂DS₂-VASc score

-

-

-

Annual stroke risk
-
estimated / year
Anticoagulation
-
educational context
Age points
-
points
Sex points
-
points
CHF / HTN / DM / V
-
points
Stroke / TE
-
points

How to Use the CHA₂DS₂-VASc Calculator

1
Confirm the patient has non-valvular atrial fibrillation (or the indication specified in your guideline or protocol).
2
Enter age and sex category. Age contributes either 0, 1, or 2 points depending on the 65 and 75 year thresholds.
3
Mark each clinical risk factor present: CHF/LV dysfunction, hypertension, diabetes, prior stroke/TIA/thromboembolism, and vascular disease.
4
Review the total score, estimated annual stroke risk, and anticoagulation recommendation band alongside HAS-BLED bleeding risk and patient preferences.

Worked Example

Example calculation

Patient: 78-year-old woman with hypertension, type 2 diabetes, and no prior stroke or vascular disease.

Points: Age ≥75 (+2), female sex (+1), hypertension (+1), diabetes (+1) = 5 points.

Interpretation: Estimated annual stroke risk ≈ 6.7%/year without anticoagulation. Educational anticoagulation context: oral anticoagulation typically recommended (score ≥2). Assess HAS-BLED and shared decision-making before therapy selection.

Anticoagulant Trials and Endpoint Context for Pharma Professionals

CHA₂DS₂-VASc stratification underpins enrollment and subgroup reporting in landmark AFib anticoagulation trials. RE-LY (dabigatran), ROCKET-AF (rivaroxaban), ARISTOTLE (apixaban), and ENGAGE AF-TIMI 48 (edoxaban) used stroke or systemic embolism as primary efficacy endpoints, with major bleeding as a core safety outcome—patterns that define modern DOAC labels and pharmacoeconomic models.

Next-generation programs—oral factor XIa inhibitors, once-weekly agents, and left atrial appendage occlusion—still reference CHA₂DS₂-VASc or CHA₂DS₂-VA thresholds for inclusion, stratification, and health technology assessment. Trial designers pair stroke risk scores with bleeding scores (HAS-BLED) when defining benefit–risk narratives for regulators and payers.

When interpreting trial results for medical affairs or competitive intelligence, distinguish absolute event rates (relevant for NNT) from relative risk reductions across CHA₂DS₂ strata. Use our NNT Calculator to translate trial event rates into patient-level effect sizes.

Limitations and Caveats

CHA₂DS₂-VASc estimates thromboembolic risk in AFib populations; it does not quantify bleeding risk, renal clearance, drug interactions, or frailty. The female sex point is contested in contemporary guidelines—2024 ESC favors CHA₂DS₂-VA without sex scoring for anticoagulation decisions.

Do not apply this score to valvular AFib (mechanical valve or moderate–severe mitral stenosis), transient AFib after surgery without recurrence, or patients already anticoagulated for another indication without reassessing the full clinical picture.

Annual stroke risk percentages are population averages from historical cohorts; individual risk may differ with comorbidity burden, AFib burden, biomarkers, and imaging findings. Always integrate guideline-directed therapy, HAS-BLED assessment, and patient-centered shared decision-making.

Interpretation Reference Table

Score Annual stroke risk (approx.) Anticoagulation context (educational)
0 0% Men: no anticoagulation. Women with score 0: no anticoagulation.
1 1.3% Men: consider anticoagulation (shared decision). Women: often female sex only—many guidelines no longer anticoagulate (see CHA₂DS₂-VA).
2 2.2% Oral anticoagulation recommended unless contraindicated.
3 3.2% Oral anticoagulation recommended.
4 4.0% Oral anticoagulation recommended.
5 6.7% Oral anticoagulation recommended; higher event rates support DOAC vs aspirin comparisons in trials.
6 9.8% Oral anticoagulation recommended; prioritize agent selection and bleeding mitigation.
7 9.6% Oral anticoagulation recommended; high stroke risk stratum.
8 12.5% Oral anticoagulation recommended; consider specialist review.
9 15.2% Oral anticoagulation recommended; highest stroke risk category.

Evidence & sources

Frequently Asked Questions

The CHA₂DS₂-VASc score estimates annual stroke risk in patients with non-valvular atrial fibrillation (AFib). It combines congestive heart failure, hypertension, age, diabetes, prior stroke or thromboembolism, vascular disease, and sex category into a 0–9 point scale used to guide oral anticoagulation decisions.
Each letter adds points: Congestive heart failure or LV dysfunction (+1), Hypertension (+1), Age ≥75 (+2) or 65–74 (+1), Diabetes (+1), prior Stroke/TIA/thromboembolism (+2), Vascular disease such as MI, PAD, or aortic plaque (+1), and female Sex category (+1). Male sex adds 0 points. Age categories are mutually exclusive.
CHA₂DS₂-VA removes the female sex point from the score, reflecting updated evidence that sex alone is a weaker stroke risk modifier when other factors are absent. The 2024 ESC AF guidelines emphasize CHA₂DS₂-VA for anticoagulation decisions, while CHA₂DS₂-VASc remains widely used in clinical practice, registries, and historical trial literature.
Educational interpretation: men with score 0 and women with score 1 (female sex only) are generally low risk and anticoagulation is usually not indicated. Men with score 1 may warrant shared decision-making. Scores ≥2 typically support oral anticoagulation unless bleeding risk or patient preference dictates otherwise. Always apply current ESC, AHA/ACC/HRS, or local guidelines.
Validated cohort data approximate annual stroke risk from about 0% at score 0 to roughly 15% at score 9, with intermediate steps near 1.3% (score 1), 2.2% (score 2), 3.2% (score 3), 4.0% (score 4), 6.7% (score 5), and 9.8% (score 6). These are population estimates for untreated or non-anticoagulated AFib and should not replace individualized assessment.
Female sex was incorporated because women with AFib had higher stroke rates in some observational datasets after adjusting for other risk factors. Subsequent analyses showed much of the excess risk in low-score women was attributable to the sex point itself, prompting guideline shifts toward CHA₂DS₂-VA. Sex remains in CHA₂DS₂-VASc for backward compatibility and trial stratification.
Vascular disease includes prior myocardial infarction, peripheral artery disease, or aortic atherosclerotic plaque (including complex plaque on imaging). Coronary artery disease without MI, carotid stenosis without stroke, or silent atherosclerosis not meeting protocol definitions may not qualify—confirm against the source document or guideline definition.
The +2 point applies to prior ischemic stroke, transient ischemic attack, or systemic thromboembolism (e.g., pulmonary embolism or peripheral arterial embolism attributed to AFib). The timing and adjudication method matter in trials; some protocols require documented events within a look-back window.
Pivotal DOAC trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48) enrolled AFib patients with stroke risk sufficient to warrant anticoagulation—predominantly CHA₂DS₂ scores ≥2 or guideline-equivalent criteria. Trial endpoints (stroke/systemic embolism, major bleeding, mortality) inform label indications and remain central to anticoagulant development and health technology assessment.
Sponsors use CHA₂DS₂-VASc or CHA₂DS₂-VA for patient enrichment, stratification, and subgroup analyses in AFib and anticoagulation trials. Stroke or systemic embolism is a standard primary efficacy endpoint; major bleeding (often with HAS-BLED context) is a key safety endpoint. Novel anticoagulants, factor XI inhibitors, and device-based stroke prevention programs reference these risk strata in protocol design.
The score does not incorporate bleeding risk (use HAS-BLED separately), renal function, frailty, polypharmacy, or patient values. It was derived largely from European cohorts with non-valvular AFib. It may perform differently in valvular AFib, post-ablation patients, or brief AFib episodes. Scores are screening tools, not substitutes for multidisciplinary stroke prevention decisions.
CHA₂DS₂-VASc addresses thromboembolic stroke risk; HAS-BLED estimates major bleeding risk on anticoagulation. Guidelines recommend balancing both when deciding on oral anticoagulation, agent selection, and monitoring intensity. High stroke risk does not automatically contraindicate anticoagulation, and elevated HAS-BLED warrants closer follow-up rather than withholding anticoagulation in most high-risk stroke patients.

Related Tools

HB HAS-BLED Score HE HEART Score QT QTc Calculator NNT NNT Calculator

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.